中重度创伤性脑损伤患者:伤前血小板抑制剂或华法林治疗的影响
该研究纳入184例≥50岁中重度创伤性脑损伤(TBI)患者,评估伤前抗血栓药物对临床与影像学神经恶化的影响及对结局的作用。血小板抑制剂组未显著增加神经恶化或预测死亡/不良结局,而华法林组神经恶化频率增加,且为死亡和6个月不良结局的独立危险因素。作者认为跌倒预防和宽松使用CT检查对该患者群体重要。
要点
- 伤前血小板抑制剂未显著增加临床或影像学神经恶化,也未预测死亡或不良结局。
- 伤前华法林增加GCS评分和Rotterdam CT评分恶化的频率,并独立预测死亡和不良结局。
- 作者认为跌倒预防和宽松使用CT检查对中重度TBI患者群体重要。
核心结论
- 伤前血小板抑制剂未导致神经恶化,也未预测更高死亡率或更差结局。
- 伤前华法林导致神经恶化,且为死亡和6个月不良结局的独立危险因素。
- 作者认为跌倒预防和宽松使用CT检查对该患者群体重要。
研究设计与样本
- 连续纳入184例≥50岁中重度TBI患者,收治于一级创伤中心。
- 临床神经恶化采用GCS评分评估,影像学恶化采用Rotterdam CT评分在重复时间点评估。
- 伤后6个月采用扩展格拉斯哥结局量表评估功能结局。
主要发现
- 血小板抑制剂组平均年龄77.3岁(n=43),华法林组平均年龄73.2岁(n=20),均显著高于非用药组平均年龄63.7岁(n=121;P ≤ 0.001)。
- 血小板抑制剂组74%和华法林组85%因跌倒受伤。
- 血小板抑制剂与临床或影像学神经恶化无显著关联(P = 0.37-1.00)。
- 华法林增加GCS评分恶化频率(P = 0.001-0.028)和Rotterdam CT评分恶化频率(P = 0.004)。
- 院内死亡率血小板抑制剂组28%(P = 0.030)和华法林组50%(P < 0.001)高于非用药组13%。
临床怎么用
- 作者认为跌倒预防和宽松使用CT检查对该患者群体重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to examine the effect of preinjury antithrombotic medication on clinical and radiologic neuroworsening in traumatic brain injury (TBI) and study the effect on outcome. METHODS: A total of 184 consecutive patients ≥50 years old with moderate and severe TBI admitted to a level 1 trauma center were included. Neuroworsening was assessed clinically by using the Glasgow Coma Scale (GCS) score and radiologically by using the Rotterdam CT score on repeated time points. Functional outcome was assessed with the Glasgow Outcome Scale Extended 6 months after injury. RESULTS: The platelet inhibitor group (mean age, 77.3 years; n = 43) and the warfarin group (mean age, 73.2 years; n = 20) were significantly older than the nonuser group (mean age, 63.7 years; n = 121; P ≤ 0.001). In the platelet inhibitor group 74% and in the warfarin group, 85% were injured by falls. Platelet inhibitors were not significantly associated with clinical or radiologic neuroworsening (P = 0.37-1.00), whereas warfarin increased the frequency of worsening in GCS score (P = 0.001-0.028) and Rotterdam CT score (P = 0.004). In-hospital mortality was higher in the platelet inhibitor group (28%; P = 0.030) and the warfarin group (50%; P < 0.001) compared with the nonuser group (13%). Platelet inhibitors did not predict mortality or worse outcome after adjustment for age, preinjury disability, GCS score, and Rotterdam CT score, whereas warfarin predicted both mortality and worse outcome. CONCLUSIONS: In this study of patients with moderate and severe TBI, preinjury platelet inhibitors did not cause neuroworsening or predict higher mortality or worse outcome. In contrast, preinjury warfarin caused neuroworsening and was an independent risk factor for mortality and worse outcome at 6 months. Hence, fall prevention and liberal use of computed tomography examinations is important in this patient group.
引用
- Tollefsen MH, Vik A, Skandsen T, et al. Patients with Moderate and Severe Traumatic Brain Injury: Impact of Preinjury Platelet Inhibitor or Warfarin Treatment. World Neurosurg. 2018. PMID: 29524716. doi:10.1016/j.wneu.2018.02.167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。